Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs

Pharmacology

Volumn 62, Issue 2, 2001, Pages 65-72

  Misawa, Keiko ^a   Ichikawa, Kiyoshi ^a   Ojima, Kazuma ^a   Hamano, Shuichiro ^a   Kitamura, Tsuyoshi ^a   Komatsu, Hidetada ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Dog; Hypoglycemic agent; Impaired glucose tolerance (IGT); Non insulin dependent diabetes mellitus; Portal venous blood; Postprandial hyperglycemia; Streptozotocin; Sulfonylureas (SUs); Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; GLUCOSE; INSULIN; MITIGLINIDE; STREPTOZOCIN; SULFONYLUREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PORTAL VEIN BLOOD; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOGS; GLICLAZIDE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INDOLES; INSULIN; MALE; STREPTOZOCIN;

EID: 0035129490     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056073     Document Type: Article

References (25)

1. Treatment of NIDDM patients with peroral antidiabetic drugs: Sulfonylureas, biguanides and new pharmacological approaches
2. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM
3. Effects of change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance
4. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
5. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance
6. The postprandial state: Mechanisms of glucose intolerance
7. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects
8. The postprandial state and the risk of atherosclerosis
9. Novel rapid-and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: Comparison of effects between KAD-1229 and gliclazide
10. In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dehydrate (KAD-1229), in rat pancreatic B-cells
11. Effect of a non-sulfonylurea hypoglycemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat
12. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dehydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats
13. A rapid and short hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats
14. Diabetogenic action of streptozotocin: Relationship of dose to metabolic response
15. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets
16. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
17. The metabolism of gliclazide in man
18. Pancreatic hormones and antidiabetic drugs
19. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas
20. Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus
21. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis
22. Coronary-heart-disease risk and impaired glucose tolerance: The Whitehall Study
23. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
24. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus